VRF-CDSI India Special Research Grant
VRF in collaboration with Cosmetic Dermatology Society of India (CDSI) is proud to announce a Special Call for Research Grant Proposals 2012 focused exclusively on India.
Results of epidemiological studies indicate that vitiligo prevalence in India is the highest in the world reaching 8.8% of population affected, thus making India an "epicenter" of vitiligo. On top of that, vitiligo problem in India is further scrutinized by social and cultural features. Together, this makes vitiligo an important issue in India, and places development of novel vitiligo treatment modalities on high demand.
VRF will provide an award for $25,000* for a period of one year to fund an outstanding research proposal(s) in vitiligo area, which is originating from India. According to the VRF's mission, the proposed research could range from basic to clinical science, and its expected results should clearly contribute to development of novel treatment modalities of vitiligo or provide firm scientific basis for that.
We encourage Indian researchers to submit short research proposals to VRF in according to VRF Grant Pre-Application Form for a first round of evaluation. Selected applicants will be eligible to submit full research proposals which will be peer-reviewed to select the most prominent application for funding.
Overview of eligibility criteria and conditions
Principal investigator of the proposed project should have a full-time position in India-based research or clinical unit. Research conducted outside India is not eligible for support under this VRF India Special Grant.
Proposed research should clearly contribute to development of novel treatment modalities of vitiligo or provide firm scientific basis for that.
Approved research project will be financed based on the VRF Research Grant Agreement between VRF and administering organization with which project Principal investigator is affiliated.
Allocated for the winning award funding will be wire-transferred in full as a single payment to the Principal investigator's administering organization.
Grant award is subjected to obligation to submit final report on the work done in the frame of the project within 1 month after project completion.
If awarded, funding should be spent solely to conduct research described in the proposal at the Principal investigator's discretion.Deadlines
April 30, 2012 – Deadline for application pre-submission (short research proposal) for the first round of evaluation.
May 30, 2012 – Announcement of the first round evaluation results and invitation to submit research proposal in full.
August 31, 2012 – Deadline for full proposal submission.
October 30, 2012 – Announcement of grant award
* VRF does not take any commitments to award the grant which will be done solely on the VRF's discretion and is subjected to high scientific quality of the proposal and its significant contribution to unraveling the mystery of vitiligo at a molecular, epidemiological or clinical level.
I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.
What is coming?
May 24, 2013: VRF Presentation at EADV Spring Symposium
Sodium oxodihydroacridinylacetate in treatment of active vitiligo. Results of preliminary clinical study.
What causes vitiligo?
It remains unclear what causes damage to melanocytes and their subsequent total inactivation and/or disappearance in vitiligo skin. There are several theories; the mos...
How can I treat vitiligo?
Choosing a treatment for vitiligo can be difficult, sometimes overwhelming. In general, first-line therapy should be safe, effective, minimally invasive, and cost effi...
Is it possible to stop the progression of vitiligo?
Vitiligo is progressive in 73% of cases and regressive in 1.3%. We usually explain to the patients that progression depends on the modality of the disease spreading: l...
I have vitiligo: will my children have vitiligo too?
Although most cases of vitiligo are sporadic, familial clustering is not uncommon, and up to 20% of patients report on the affected relatives. In whites, the lifetime ...